Mitch Dowsett
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
Dowsett, Mitch; Goldstein, Neil S.; Hicks, David G.; Mangu, Pamela B.; Osborne, C. Kent; Sweep, Fred C.G.; Wittliff, James L.; Dowsett, Mitchell; Hammond, M. Elizabeth H.; Hayes, Daniel F.; Allred, D. Craig; Hagerty, Karen L.; Badve, Sunil; Fitzgibbons, Patrick L.; McShane, Lisa M.; Francis, Glenn; Hayes, Malcolm; Lester, Susan; Love, Richard; Sweep, Fred CG; Miller, Keith; Paik, Soonmyung; Perlmutter, Jane; Rhodes, Anthony; Sasano, Hironobu; Schwartz, Jared N.; Taube, Sheila; Torlakovic, Emina Emilia; Valenstein, Paul; Viale, Giuseppe; Visscher, Daniel; Wheeler, Thomas; Williams, R. Bruce; Wolff, Antonio C.
Authors
Neil S. Goldstein
David G. Hicks
Pamela B. Mangu
C. Kent Osborne
Fred C.G. Sweep
James L. Wittliff
Mitchell Dowsett
M. Elizabeth H. Hammond
Daniel F. Hayes
D. Craig Allred
Karen L. Hagerty
Sunil Badve
Patrick L. Fitzgibbons
Lisa M. McShane
Glenn Francis
Malcolm Hayes
Susan Lester
Richard Love
Fred CG Sweep
Keith Miller
Soonmyung Paik
Jane Perlmutter
Anthony Rhodes
Hironobu Sasano
Jared N. Schwartz
Sheila Taube
Emina Emilia Torlakovic
Paul Valenstein
Giuseppe Viale
Daniel Visscher
Thomas Wheeler
R. Bruce Williams
Antonio C. Wolff
Abstract
Purpose: To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers. Methods: The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER/PgR testing performance. Results: Up to 20% of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in preanalytic variables, thresholds for positivity, and interpretation criteria. Recommendations: The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials. © 2010 by American Society of Clinical Oncology and College of American Pathologists.
Citation
Wittliff, J. L., Sweep, F. C., Osborne, C. K., Mangu, P. B., Hicks, D. G., Goldstein, N. S., …Wolff, A. C. (2010). American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of Clinical Oncology, 28(16), 2784-2795. https://doi.org/10.1200/JCO.2009.25.6529
Journal Article Type | Review |
---|---|
Publication Date | Jun 1, 2010 |
Deposit Date | Jan 26, 2011 |
Journal | Journal of Clinical Oncology |
Print ISSN | 0732-183X |
Electronic ISSN | 1527-7755 |
Publisher | American Society of Clinical Oncology |
Peer Reviewed | Peer Reviewed |
Volume | 28 |
Issue | 16 |
Pages | 2784-2795 |
DOI | https://doi.org/10.1200/JCO.2009.25.6529 |
Keywords | breast cancer, immunohistochemical testing |
Public URL | https://uwe-repository.worktribe.com/output/978254 |
Publisher URL | http://dx.doi.org/10.1200/JCO.2009.25.6529 |